MediGene sells Eligard royalties

MediGene AG (Xetra:MDG) sold Cowen Healthcare Royalty Partners a 2% royalty on European sales of Eligard leuprolide for $17.7 million in cash. The royalty comes from MediGene's 2010 deal that gave Astellas Pharma Inc. (Tokyo:4503) European rights to the prostate cancer drug for EUR 25 million ($33.2 million). Astellas reported Y13.8 billion ($167 million) in European sales of Eligard for its fiscal year ending March 31. ...